Lv21
150 积分 2023-08-22 加入
Design and biological evaluation of triagonist GLP-1R/GCGR/GIPR peptides as potential therapeutic agents for diabetes and obesity
6小时前
已完结
Advances in incretin-based drug discovery in 2025
6小时前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
6小时前
已完结
Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects
6小时前
已完结
Crystal structure of TPR domain of CHIP complexed with pseudophosphorylated Smad1 peptide
2个月前
已关闭
A Bioinformatics Pipeline for Investigating Molecular Evolution and Gene Expression using RNA-seq
5个月前
已关闭
The Design of a GLP‐1/PYY Dual Acting Agonist
5个月前
已完结
Chromosome-level scaffolding of haplotype-resolved assemblies using Hi-C data without reference genomes
6个月前
已完结
Angiotensin (1–7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor
9个月前
已完结
The Power of Three: Retatrutide’s Role in Modern Obesity and Diabetes Therapy
9个月前
已完结
皖公网安备34019202002308
